Elanco Animal Health Inc

Elanco Animal Health Inc

ELAT
Elanco Animal Health IncUS flagNew York Stock Exchange
21.32
USD
+0.22
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
United States of America
IPO Date
Jan 30, 2020
Business
Elanco Animal Health Inc (NYSE: ELAT) develops, manufactures, and markets products for companion and food animals worldwide. The company offers pharmaceuticals, parasiticide products, vaccines, and therapeutics for pets including dogs, cats, and horses; antibiotics, parasiticides, vaccines, and enzymes for livestock such as ruminants, poultry, and swine; as well as medicated feed additives, nutritional feed products, and diagnostics. Elanco operates in over 90 countries, with a primary focus on North America, Europe, Latin America, and Asia-Pacific, targeting veterinarians, livestock producers, and pet owners. Founded in 2013 as a spin-off from Eli Lilly and Company, the company is headquartered in Greenfield, Indiana.